Dow Jones
38.503,69 +263,71 (+0,69%) Nasdaq
15.696,64 +245,33 (+1,59%) Nikkei 225
38.416,39 +864,23 (+2,30%) EUR/USD
1,0711 +0,0007 (+0,06%) Bitcoin EUR
62.278,12 +112,32 (+0,18%) CMC Crypto 200
1.434,63 +19,87 (+1,40%)
Takeda Pharmaceutical Company Limited (TKPHF)
| Chiusura precedente | 25,77 |
| Aperto | 26,53 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 25,77 - 25,77 |
| Intervallo di 52 settimane | 25,77 - 34,47 |
| Volume | |
| Media Volume | 10.024 |
| Capitalizzazione | 41,77B |
| Beta (5 anni mensile) | 0,54 |
| Rapporto PE (ttm) | 35,30 |
| EPS (ttm) | 0,73 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | 1,24 (4,82%) |
| Data ex dividendo | 28 mar 2024 |
| Stima target 1A | N/D |
GlobeNewswireHUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan
— Third major market authorization application based on data from the FRESCO-2 global Phase III trial —HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (“HUTCHMED”) today announced that Takeda (TSE:4502/NYSE:TAK) has submitted a New Drug Application (“NDA”) to the Ministry of Health, Labour and Welfare (“MHLW”) in Japan for the approval of fruquintinib for the treatment of adult patients with previously
- GlobeNewswire
HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet
— Publication shows FRESCO-2 demonstrated treatment with fruquintinib reduced the risk of death by 34% in previously treated metastatic colorectal cancer (0.66 HR) — — Data support regulatory submissions in the U.S., Europe and Japan during 2023 — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J. and OSAKA, Japan and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) and Takeda (TSE:4502, NYSE:TAK) today announced that results
GlobeNewswireCorza Medical Signs Definitive Agreement to Acquire Takeda's TachoSil Manufacturing Operations
WESTWOOD, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Corza Medical announced today that it has entered into a definitive agreement with a subsidiary of Takeda Pharmaceuticals Company (TSE:4502/NYSE:TAK) (“Takeda”) to acquire the TachoSil manufacturing operations in Linz, Austria. Corza Medical had previously acquired the commercial product rights for TachoSil, a best-in-class surgical patch trusted by medical professionals worldwide, in January 2021. Corza Medical shares Takeda’s commitment to pa
